MX2023005984A - Nuevos agentes antivirales derivados de la espiropirrolidina. - Google Patents

Nuevos agentes antivirales derivados de la espiropirrolidina.

Info

Publication number
MX2023005984A
MX2023005984A MX2023005984A MX2023005984A MX2023005984A MX 2023005984 A MX2023005984 A MX 2023005984A MX 2023005984 A MX2023005984 A MX 2023005984A MX 2023005984 A MX2023005984 A MX 2023005984A MX 2023005984 A MX2023005984 A MX 2023005984A
Authority
MX
Mexico
Prior art keywords
formula
spiropyrrolidine
novel
antiviral agents
pharmaceutically acceptable
Prior art date
Application number
MX2023005984A
Other languages
English (en)
Inventor
Xiaowen Peng
Hui Cao
Yong He
Guoqiang Wang
Jiang Long
Jun Ma
Xuechao Xing
Ruichao Shen
Xuri Gao
Yat Sun Or
Wei Li
Samuel Bartlett
Joseph D Panarese
Jiajun Zhang
Nathaniel Thomas Kenton
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/479,530 external-priority patent/US11352363B1/en
Priority claimed from US17/479,244 external-priority patent/US11384090B2/en
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2023005984A publication Critical patent/MX2023005984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención describe compuestos de Fórmula (Ia) o sales farmacéuticamente aceptables de los mismos: (ver fórmula) que inhiben la actividad de replicación del coronavirus. La invención se refiere además a composiciones farmacéuticas que comprenden un compuesto de Fórmula (Ia) o sales farmacéuticamente aceptables del mismo, y métodos para tratar o prevenir una infección por coronavirus en un sujeto que lo necesite, que comprenden administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de Fórmula (Ia) o una sal farmacéuticamente aceptables del mismo.
MX2023005984A 2020-11-23 2021-11-22 Nuevos agentes antivirales derivados de la espiropirrolidina. MX2023005984A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063117170P 2020-11-23 2020-11-23
US202163142663P 2021-01-28 2021-01-28
US17/479,530 US11352363B1 (en) 2020-11-23 2021-09-20 Spiropyrrolidine derived antiviral agents
US17/479,244 US11384090B2 (en) 2020-11-23 2021-09-20 Spiropyrrolidine derived antiviral agents
PCT/US2021/060247 WO2022109363A1 (en) 2020-11-23 2021-11-22 Novel spiropyrrolidine derived antiviral agents

Publications (1)

Publication Number Publication Date
MX2023005984A true MX2023005984A (es) 2023-08-17

Family

ID=78725298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005984A MX2023005984A (es) 2020-11-23 2021-11-22 Nuevos agentes antivirales derivados de la espiropirrolidina.

Country Status (13)

Country Link
EP (1) EP4001279A1 (es)
JP (1) JP2023551174A (es)
KR (1) KR20230124582A (es)
CN (1) CN114524821A (es)
AU (1) AU2021381437A1 (es)
CA (1) CA3173333A1 (es)
CL (1) CL2023001476A1 (es)
CO (1) CO2023008018A2 (es)
IL (1) IL302991A (es)
MX (1) MX2023005984A (es)
TW (1) TW202237616A (es)
UY (1) UY39529A (es)
WO (1) WO2022109363A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN117751124A (zh) * 2021-12-17 2024-03-22 南京药石科技股份有限公司 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途
US12006291B2 (en) 2022-01-11 2024-06-11 Enanta Pharmaceuticals, Inc. Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid
WO2023177854A1 (en) * 2022-03-18 2023-09-21 Enanta Pharmaceuticals, Inc. Processes for the preparation of substituted spirooxindole derivatives
CN116621918B (zh) * 2022-07-20 2023-10-31 深圳信立泰药业股份有限公司 一种螺环化合物及其制备方法与应用
CN115466189B (zh) * 2022-09-19 2024-08-30 安徽普利药业有限公司 一种氨基酸及其衍生物的纯化方法
US20240132512A1 (en) * 2022-10-06 2024-04-25 Enanta Pharmaceuticals, Inc. Crystal forms of an anti-sars cov-2 agent
CN115894504A (zh) * 2022-10-21 2023-04-04 深圳信立泰药业股份有限公司 一种冠状病毒3cl蛋白酶抑制剂及其用途
US20240199647A1 (en) * 2022-11-02 2024-06-20 Aligos Therapeutics, Inc. Anti-viral compounds
CN117986260A (zh) * 2022-11-03 2024-05-07 中国科学院上海药物研究所 一类螺环化合物、其制备方法及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
EP1628674A2 (en) 2003-05-06 2006-03-01 Cytovia, Inc. Protease inhibitors for coronaviruses and sars-cov and the use thereof
WO2004101781A1 (en) 2003-05-13 2004-11-25 Universität Zu Lübeck Crystal structure of human coronavirus 229e main proteinase, and uses thereof for developing sars inhibitors
US20060014821A1 (en) 2003-08-27 2006-01-19 Agouron Pharmaceuticals, Inc. Inhibitors of SARS 3C like protease
US7462594B2 (en) 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2006061714A2 (en) 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
MY160077A (en) * 2011-01-21 2017-02-15 Univ Sains Malaysia Curcumin compounds and their preparations thereof
US9474759B2 (en) 2011-09-27 2016-10-25 Kansas State University Research Foundation Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
US9309284B2 (en) 2012-05-02 2016-04-12 Kansas State University Reasearch Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, caliciviruses and coronaviruses
US11013779B2 (en) * 2016-06-20 2021-05-25 Kansas State University Research Foundation Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses
US11033600B2 (en) 2016-07-28 2021-06-15 Kansas State University Research Foundation Protease transition state inhibitor prodrugs
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法

Also Published As

Publication number Publication date
TW202237616A (zh) 2022-10-01
JP2023551174A (ja) 2023-12-07
WO2022109363A1 (en) 2022-05-27
CA3173333A1 (en) 2022-05-27
EP4001279A1 (en) 2022-05-25
CO2023008018A2 (es) 2023-07-10
KR20230124582A (ko) 2023-08-25
UY39529A (es) 2022-06-30
CL2023001476A1 (es) 2023-12-11
IL302991A (en) 2023-07-01
CN114524821A (zh) 2022-05-24
AU2021381437A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
MX2023007192A (es) Inhibidores de prmt5.
MX2022003984A (es) Compuestos heterociclicos antivirales.
MX2021013934A (es) Compuestos y metodos para el tratamiento de covid-19.
TW200518758A (en) HIV replication inhibiting purine derivatives
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
SE9901573D0 (sv) New compounds
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2024001377A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
SE9901572D0 (sv) New compounds
MX2023009961A (es) Compuestos heterociclicos antivirales.
SE0201837D0 (sv) Chemical compounds
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
WO2024107783A3 (en) Novel macrocyclic chalcone-amide derived antiviral agents